<DOC>
	<DOCNO>NCT00971126</DOCNO>
	<brief_summary>The purpose phase I study determine maximal tolerable dose ( MTD ) thalidomide ( THADO® ) combination fix dose sorafenib ( NEXAVAR® ) treatment advance metastatic HCC . The Phase II purpose study determine disease control rate ( complete response + partial response + stable disease ) least 4 month sorafenib ( NEXAVAR® ) plus phase I determine MTD thalidomide ( THADO® ) patient advance metastatic HCC .</brief_summary>
	<brief_title>Study Sorafenib With Combination Thalidomide Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>This non-randomized , open-labeled , single-arm , multi-center , phase I /II clinical study . The Phase I purpose study determine maximal tolerable dose ( MTD ) thalidomide ( THADO® ) combination fix dose sorafenib ( NEXAVAR® ) treatment advance metastatic HCC , dose-limiting toxicity ( DLT ) profile toxicity profile patient receive fix dose sorafenib ( NEXAVAR® ) plus escalate dose thalidomide ( THADO ) . The Phase II primary objective study determine disease control rate ( complete response + partial response + stable disease ) least 4 month sorafenib ( NEXAVAR® ) plus phase I determine MTD thalidomide ( THADO® ) patient advance metastatic HCC . The Phase II secondary objective study determine objective tumor response rate , time tumor progression , progression-free survival , overall survival , safety adverse event profile , change circulate biomarkers relate angiogenesis correlation disease control rate . The sample size require 24 patient phase I study 53 patient phase II study . Sorafenib ( NEXAVAR® ) : supply Good Manufacturing Practice standard Bayer Health Care , Taiwan film-coated tablet , contain sorafenib tosylate ( 274mg ) equivalent 200 mg sorafenib . Thalidomide ( THADO® ) : supply Good Manufacturing Practice standard TTY Biopharm Co. , Ltd. white-yellow capsule , contain 50 mg thalidomide .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must least 18 year age . With histologically cytologically document HCC clinically diagnose HCC . Advanced ( surgically unresectable unsuitable local therapy ) , and/or metastatic HCC , and/or patient refuse local therapy . Performance status ECOG score 02 . Life expectancy least 12 week . At least one tumor lesion meet follow criterion : measurable ( must CTscan MRI ) least one dimension accord RECIST ; lesion previously treat local therapy , radiation therapy , hepatic arterial ( chemo ) embolization , radiofrequency ablation , percutaneous interventional therapy . Previous local therapy , radiotherapy , hepatic arterial ( chemo ) embolization , radiofrequency ablation , percutaneous interventional therapy , allow treatment must complete least 4 week prior baseline scan . Patients adequate bone marrow reserve define : ANC ≧ 1,500/μl ; Platelets count ≧ 75,000/μl ; Hemoglobin ≧ 8.5 g/dl . Adequate liver renal function define : ChildTurcottePugh score 7 low ( class A wellcompensated class B ) ; Liver transaminase ( ALT ) ≦ 5 x upper limit normal ( ULN ) ; Serum total bilirubin ≦ 3mg/dl ; Serum albumin ≧ 2.8 g/dl ; Prothrombin time ( PT ) internal normalize ration ( INR ) ≦ 2.3 partial thrombin time ( PTT ) ≦ 6 second control ; Serum creatinine ≦ 1.5 x ULN . Women childbearing potential men must agree use adequate contraception , prior study entry , treatment , least 3 month last dose treatment . Patients must understand protocol sign write informed consent . Previous use systemic anticancer therapy HCC chemotherapy , immunotherapy , target therapy within 4 week study entry . Patients prior use investigational drug include sorafenib thalidomide . Active cardiac disease , include CHF NYHA class &gt; 2 , active CAD , cardiac arrhythmia require antiarrhythmic therapy betablockers digoxin , uncontrolled hypertension . Patients hemorrhagic diathesis history active bleed 30 day prior study entry . History HIV infection . Active uncontrolled infection require antibiotic treatment . Metastatic brain leptomeningeal tumour unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry , clinically stable respect tumour time study entry . With seizure disorder require medication ( steroids antiepileptic ) . History organ allograft . Undergoing renal dialysis . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bluffer tumour [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . Pregnant breastfeeding patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
</DOC>